Related Experiment Videos
Lipid-lowering drug use and cardiovascular events after myocardial infarction
Olaf H Klungel1, Susan R Heckbert, Anthonius de Boer
1Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences, Sorbonnelaan 16, 3584 CA Utrecht, the Netherlands. o.h.klungel@pharm.uu.nl
Insights
Lipid-lowering drugs, including statins and non-statins, significantly reduce cardiovascular events in myocardial infarction survivors. This highlights the importance of these treatments for secondary prevention in hyperlipidemic patients.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Established benefits of lipid-lowering drugs for secondary prevention of coronary heart disease.
- Lack of direct comparison between statins and non-statin lipid-lowering drugs.
- Uncertainty regarding real-world effectiveness of lipid-lowering drugs post-myocardial infarction (MI).
Purpose of the Study:
- To evaluate the association between lipid-lowering drug therapies in routine clinical practice and cardiovascular event risk.
- Focus on patients experiencing their first MI and surviving hospitalization.
Main Methods:
- Inception-cohort study of 1956 patients with incident MI (1986-1996) surviving at least 6 months.
- Inclusion criteria: untreated LDL cholesterol >130 mg/dL or total cholesterol >200 mg/dL.
- Data collection via medical record review and computerized pharmacy records for antihyperlipidemic drug use.
Main Results:
- Statins (n=373) were associated with reduced risk of recurrent coronary events (RR 0.59) and all atherosclerotic cardiovascular events (RR 0.63) compared to no treatment.
- Non-statin therapies (n=320) showed reduced risk for recurrent coronary events (RR 0.66) and all atherosclerotic cardiovascular events (RR 0.77).
- No significant reduction in stroke or cardiovascular mortality was observed for either drug class compared to untreated patients.
Conclusions:
- Lipid-lowering drug therapies post-hospitalization are linked to decreased cardiovascular event risk in MI survivors.
- Emphasizes the critical role of lipid-lowering treatment for hyperlipidemic patients following a first MI.
- Supports the use of statins and non-statins in managing cardiovascular risk in this population.
Background:
The benefits of lipid-lowering drug treatment for the secondary prevention of coronary heart disease have been well established by randomized, controlled trials. Nonetheless, the risk of events has not been compared directly for inhibitors of hydroxymethylglutaryl coenzyme A reductase (statins) and non-statin lipid-lowering drugs. Further, it remains uncertain whether patients in usual practice who are treated with lipid-lowering drugs after myocardial infarction (MI) gain a similar benefit with regard to the risk of cardiovascular events compared with patients in randomized, controlled trials.
Objective:
To assess the association between lipid-lowering drug therapies in usual clinical practice and the risk of cardiovascular events in patients with a first MI who were discharged alive from the hospital.
Methods:
An inception-cohort study was performed among 1956 enrollees of Group Health Cooperative who sustained an incident MI between July 1986 and December 1996 and survived for at least 6 months after hospitalization. Subjects with untreated low-density-lipoprotein cholesterol concentrations > 130 mg/dL or untreated total cholesterol concentrations >200 mg/dL were included. The median duration of follow-up after the first MI was 3.3 years. Medical record review was used to collect information on cardiovascular risk factors. Computerized pharmacy records were used to assess antihyperlipidemic drug use during the first 6 months after hospitalization.
Results:
Compared with 1263 subjects who did not receive lipid-lowering drug treatment, 373 subjects who received statins had a lower risk of recurrent coronary events (relative risk [RR] 0.59; 95% CI 0.39 to 0.89), stroke (RR 0.82; 95% CI 0.35 to 1.95), atherosclerotic cardiovascular mortality (RR 0.49; 95% CI 0.21 to 1.13), and any atherosclerotic cardiovascular event (RR 0.63; 95% CI 0.40 to 0.98). Among 320 subjects who used non-statin drug therapies, the RRs were 0.66 (95% CI 0.45 to 0.97) for recurrent coronary events, 0.95 (95% CI 0.46 to 1.95) for stroke, 0.68 (95% CI 0.35 to 1.32) for cardiovascular mortality, and 0.77 (95% CI 0.53 to 1.11) for any atherosclerotic cardiovascular event, compared with untreated hyperlipidemic patients.
Conclusions:
In this study of MI survivors, the use of lipid-lowering drug therapies after hospitalization was associated with a reduced risk of cardiovascular events. These results emphasize the importance of lipid-lowering drug treatment in patients with hyperlipidemia who survive a first MI.